Shares of Evotec SE (NASDAQ:EVO - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 45,074 shares changed hands during mid-day trading, a decline of 16% from the previous session's volume of 53,452 shares.The stock last traded at $3.91 and had previously closed at $3.92.
Evotec Trading Down 0.8 %
The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The stock's 50-day moving average price is $4.30 and its 200-day moving average price is $4.09.
Institutional Investors Weigh In On Evotec
Several hedge funds and other institutional investors have recently made changes to their positions in EVO. Wellington Management Group LLP lifted its stake in shares of Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock valued at $9,616,000 after acquiring an additional 602,858 shares during the period. DCF Advisers LLC lifted its position in Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the period. Lighthouse Investment Partners LLC bought a new position in shares of Evotec in the 4th quarter valued at about $166,000. Bank of America Corp DE boosted its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Finally, CSS LLC IL acquired a new stake in shares of Evotec during the 4th quarter worth approximately $50,000. 5.81% of the stock is owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Articles
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
